Navigation Links
Independent Physician Surveys Show if Approved, MF101 Could Become First-Line Treatment for Menopause Symptoms
Date:3/10/2008

EMERYVILLE, Calif., March 10 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today results from two independent physician surveys which showed MF101 could become first-line treatment for menopausal vasomotor symptoms (hot flashes). In both qualitative and quantitative studies, 124 physicians board certified in internal medicine or obstetrics and gynecology specializing in the treatment of menopause reported MF101, if approved, would be their drug of choice for the treatment of hot flashes. In addition, 92% of physicians reported they would prescribe MF101 before prescribing an antidepressant agent for hot flashes.

"These results confirm what we have believed for over a decade. Both physicians and women are eagerly awaiting a safe and new alternative drug for the treatment of menopausal symptoms," said Mary Tagliaferri, M.D., Bionovo's President and CMO. "The multiple medical risks associated with estrogen therapies make these drugs undesirable, and the antidepressant agents currently used off label for this indication are poorly tolerated due to their many side effects. In contrast, our lead drug candidate, MF101, showed in a Phase 2 study that it is effective at alleviating hot flashes and is extremely well tolerated due to a very favorable safety profile."

In addition to placing MF101 at the top of the list of treatment options for menopausal symptoms, physicians also reported the following:
-- The accepted threshold for efficacy of a drug for vasomotor symptoms is

a 58% reduction in moderate to severe hot flashes, and,

-- The number one concern for women when considering treatment options for

menopausal symptoms is the risk of cancer.

-- Many women have foregone treatment of hot flashes, even moderate to

severe hot flashes, because of the side effects and risks of current

treatments.

"These independent physician studies provide us with further evidence that if available, MF101 can be a blockbuster drug once it hits the market," said Isaac Cohen, O.M.D., Chairman and CEO of Bionovo. "A safe and effective drug should be able to earn a large share of the $6-7 Billion of demand that existed in the past for this indication."

Complete results from the independent physician surveys are being prepared for publication.

Bionovo, Inc.

Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com.

Forward Looking Statements

This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Independent Clinical Results Confirm Up to a 7-Centimeter Reduction in Body Circumference Using UltraShape(TM) Non-Invasive Fat Reduction and Body Contouring System
2. Facet Solutions AFRS(TM) Demonstrates Biomechanical Advantages Over Dynamic Stabilization in Independent Testing
3. Video: New Research Discovers Independent Brain Networks Control Human Walking
4. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
5. Physicians Reconsider Implications of Enhance Trial
6. ReachMD Broadcasts First-of-its-Kind Physician Peer-Peer Discussion on ENHANCE Trial
7. Physicians Will Benefit from Medical Software Advice Website
8. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
9. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
10. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
11. St. Jude Finds Molecule That Could Improve Cancer Vaccine and Therapy for Other Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... INDIANAPOLIS , Feb. 12, 2016  Eli Lilly and ... High Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent ... in the UK, France , ... instructions to dilute the product only with dextrose solution.  ... of 2015, the UK Court of Appeal held that Lilly,s ...
(Date:2/12/2016)... February 12, 2016 ... auf den ungedeckten medizinischen Bedarf bei Lungen- ... seines klinischen Forschungsprogramms bekannt. Das Programm, das ... Verbesserungen ihrer respiratorischen Funktionen und anderer klinischer ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ...
Breaking Medicine Technology:
(Date:2/12/2016)... Omaha, NE (PRWEB) , ... February 12, 2016 , ... ... list of the five most searched jobs via the website of healthcare staffing leader ... professionals in travel nurse jobs , travel therapy positions and in ...
(Date:2/12/2016)... ... February 12, 2016 , ... The aging population and ... long term care. With that, says Patrick Loughney, president of Longtree & ... in long term care environments. His company, which offers prep courses and workshops ...
(Date:2/12/2016)... ... 12, 2016 , ... Basketball is a game for everyone, not just those ... series, sign language translation is featured in the top right of the screen. Every ... lessons has a sign language translator to teach kids the game and how to ...
(Date:2/12/2016)... ... February 12, 2016 , ... With the exception of restorative dentistry, to date there has been ... the recent approval by the FDA, there is a now a new protocol in stopping ... is very simple and quick to apply. The application is as simple as drying ...
(Date:2/11/2016)... ... ... Fitbody Personal Training offers outdoor training classes which includes an equestrian boot ... healthy. Located in Phoenixville, PA, the classes are structured as fun and friendly. , ... want to lose weight and tone up. This class offers a balance of exercises ...
Breaking Medicine News(10 mins):